ClinicalTrials.gg
CompletedNCT04564742DAPA-MIUpdated Mar 7, 2025Results posted

Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.

A Phase 3 interventional study of Dapagliflozin and Placebo in Acute Myocardial Infarction and Heart Failure, sponsored by AstraZeneca. Completed at 103 sites in 2 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,017
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.

Enrollment
5th of 59
4,017 · median 100
Started
2020
with 7 others
Phase 3
16 of 59
5 open now
Registered
16th of 59
by date
Lead sponsor
7 of 59
AstraZeneca

Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 5th largest by enrollment, is one of 8 that started in 2020, is one of 16 in phase 3, and was the 16th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing dapagliflozin in Heart Failure, or all of them as a file.
02

Study summary

This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF), cardiovascular (CV) death, and other cardiometabolic outcomes.

Read the detailed description

This is a multicentre, parallel group double-blind, placebo-controlled phase 3 registry-based randomised controlled trial (R-RCT) in patients without diabetes presenting with myocardial infarction (MI) (ST segment elevation myocardial infarction (STEMI) or non-ST segment elevation myocardial infarction (NSTEMI)) and evidence of impaired regional or global LV systolic function or definite evidence of Q wave MI on ECG. In the study the effect of dapagliflozin versus placebo, given once daily in addition to SoC therapy will be evaluated for the hospitalisation for HF, CV death, and other cardiometabolic outcomes.

03

Conditions studied

  • Acute Myocardial Infarction
  • Heart Failure

Keywords

  • Myocardial Infarction
  • Cardiovascular Outcome Trial
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥18 at the time of signing the
  • Confirmed MI, either STEMI or NSTEMI, according to the fourth universal definition of MI (Thygesen et al 2019), within the preceding 7 days, or 10 days if earlier randomisation is not feasible
  • Evidence of impaired regional or global LV systolic function at any timepoint during current MI-related hospitalisation (established with echocardiogram, radionuclide ventriculogram, contrast angiography or cardiac MRI) or definitive evidence on of Q wave MI (defined as presence of Q waves in two or more contiguous leads, excluding leads III and aVR, and meeting all the following criteria: at least 1.5 mm in depth; at least 30 ms in duration; and, if R wave present, more than 25% of the size of the subsequent R wave)
  • Hemodynamically stable at randomization (no episodes of symptomatic hypotension, or arrhythmia with haemodynamic compromise in the last 24 hours).
  • Male or female
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
  • Provision of signed and dated, written informed consent prior to any mandatory study specific procedures, sampling, and analyses

Exclusion criteria

Exclusion Criteria:

  • Known type 1 diabetes mellitus (T1DM) or T2DM at the time for admission. Patients with hyperglycaemia, but without a diagnosis of diabetes mellitus prior to the index event, are eligible at the discretion of the Investigator. Patients who present with signs and symptoms consistent with ketoacidosis, including nausea, vomiting, abdominal pain, malaise and shortness of breath should be assessed for ketoacidosis, and if ketoacidosis is confirmed the patient should not be randomized.
  • Chronic symptomatic HF with a prior HHF within the last year and known reduced (LVEF≤40 %), documented before the current MI hospitalization
  • Severe ( \<20 mL/min/1.73 m2 by local laboratory), unstable or rapidly progressing renal disease at the time of randomization
  • Severe hepatic impairment ( class C) at the time of inclusion into the trial
  • Active requiring treatment at the time of screening, except for basal cell- or squamous cell carcinoma of the skin, presumed possible to treat successfully
  • Any non-CV condition, eg malignancy, with a of less than two years based on the investigator´s clinical judgement
  • Currently on treatment, or with an indication for treatment, with a sodium glucose co-transporter 2 inhibitor (SGLT2-inhibitor)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,017 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    Patients will be randomized 1:1 to either dapagliflozin or placebo

    Drug: Dapagliflozin

  • Placebo comparator
    Placebo

    Placebo matching dapagliflozin

    Drug: Placebo

Interventions

  • Dapagliflozin 10 mg tablets given once daily, per oral use

    Also known as: Forxiga TM, Farxiga TM

  • DrugPlacebo

    Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use

06

What researchers measure

Primary outcomes

  1. Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set)

    Study participants received dapagliflozin 10 mg or matching placebo, given once daily in addition to SoC. Overall, the mean study duration was 12.0 months (time in study until last visit) with an accumulated 4023.9 participant-years. The maximum study duration for any participant was 29 months. "Number of Events" for NYHA corresponds to the number of participants with a non-missing value for NYHA functional class at the last visit, and that all participants with a non-missing value take part in the analysis comparing their NYHA class value with all other participants with a NYHA value, according to the win-ratio method.

    Time frame: 29 months

07

Results

Posted Mar 7, 2025

Participant flow

Participant flow — Overall Study
MilestoneDapa 10 mgPlacebo
Started20191998
Completed20141994
Not completed54
Withdrew: Lost to follow-up10
Withdrew: Consent withdrawal44

Outcome measures

PrimaryAnalysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set)

Study participants received dapagliflozin 10 mg or matching placebo, given once daily in addition to SoC. Overall, the mean study duration was 12.0 months (time in study until last visit) with an accumulated 4023.9 participant-years. The maximum study duration for any participant was 29 months. "Number of Events" for NYHA corresponds to the number of participants with a non-missing value for NYHA functional class at the last visit, and that all participants with a non-missing value take part in the analysis comparing their NYHA class value with all other participants with a NYHA value, according to the win-ratio method.

Time frame:
29 months
Reported as:
Count of participants · Participants
Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set)
ParticipantsDapa 10 mgPlacebo
The hierachical composite endpoint of all components19901970
Death, adjudicated4133
Hospitalisation due to HF3241
Non-fatal MI2932
AF/Flutter event815
New onset of T2DM4074
NYHA Classification at last visit, measuring limitations of physical activity18391773
Body Weight decrease of at least 5% at last visit684468
Statistical analysis
  • Dapa 10 mg vs Placebo · Win Ratio Analysis · p = <0.001 (A closed testing procedure including a pre-specified hierarchical ordering of the primary and secondary endpoints was utilised. No multiplicity control was placed on the exploratory endpoints.) · Win ratio (wr): 1.34 · 95% CI 1.20 to 1.50

Adverse events

Collected over Time frame was from date of randomization and up to and including last day in study, up to 29 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapa 10 mg41/2,019 (2%)449/2,019 (22.2%)0/2,019 (0%)
Placebo33/1,998 (1.7%)404/1,998 (20.2%)0/1,998 (0%)
Most frequent serious events
Showing 10 of 353
Most frequent serious events
EventDapa 10 mgPlacebo
Cardiac failureCardiac disorders40/201939/1998
Non-cardiac chest painGeneral disorders39/201930/1998
Acute myocardial infarctionCardiac disorders36/201936/1998
Angina pectorisCardiac disorders33/201932/1998
Chest painGeneral disorders16/201924/1998
PneumoniaInfections and infestations22/201915/1998
Angina unstableCardiac disorders20/201917/1998
Atrial fibrillationCardiac disorders11/201918/1998
Acute kidney injuryRenal and urinary disorders14/201916/1998
SyncopeNervous system disorders14/201910/1998

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dapa 10 mgPlaceboTotal
Age (Years)63.0 ± 11.0662.8 ± 10.6462.9 ± 10.85
Age, Customized
Age, Customized(Participants)Dapa 10 mgPlaceboTotal
>65 years8317991630
<=65 years118811992387
Sex: Female, Male
Sex: Female, Male(Participants)Dapa 10 mgPlaceboTotal
Female388419807
Male163115793210
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapa 10 mgPlaceboTotal
American Indian or Alaska Native000
Asian6452116
Black or African American81523
Native Hawaiian or other Pacific Islander000
Other403777
White190518933798
MISSING213
08

Study locations

103 sites
  • Research Site
    Alingsås, 44183, Sweden
  • Research Site
    Borås, 501 02, Sweden
  • Research Site
    Eskilstuna, 631 88, Sweden
  • Research Site
    Falun, 791 82, Sweden
  • Research Site
    Gävle, 801 88, Sweden
  • Research Site
    Göteborg, 413 45, Sweden
  • Research Site
    Göteborg, 416 85, Sweden
  • Research Site
    Halmstad, 30185, Sweden
  • Research Site
    Helsingborg, 251 87, Sweden
  • Research Site
    Hässleholm, 281 25, Sweden
  • Research Site
    Jönköping, 551 85, Sweden
  • Research Site
    Kalix, 952 82, Sweden
  • Research Site
    Karlshamn, 374 80, Sweden
  • Research Site
    Karlskoga, 691 81, Sweden
  • Research Site
    Karlskrona, 371 41, Sweden
  • Research Site
    Karlstad, 651 85, Sweden
  • Research Site
    Kiruna, 981 28, Sweden
  • Research Site
    Köping, 731 81, Sweden
  • Research Site
    Lidköping, 531 85, Sweden
  • Research Site
    Linköping, 581 85, Sweden
  • Research Site
    Lund, 222 42, Sweden
  • Research Site
    Malmö, 205 02, Sweden
  • Research Site
    Mölndal, 431 80, Sweden
  • Research Site
    Norrköping, 603 79, Sweden
  • Research Site
    Skellefteå, 931 86, Sweden
  • Research Site
    Stockholm, 112 81, Sweden
  • Research Site
    Stockholm, 118 83, Sweden
  • Research Site
    Stockholm, 141 86, Sweden
  • Research Site
    Stockholm, 171 76, Sweden
  • Research Site
    Stockholm, 182 88, Sweden
  • Research Site
    Trollhättan, 461 73, Sweden
  • Research Site
    Umeå, 90737, Sweden
  • Research Site
    Uppsala, 75185, Sweden
  • Research Site
    Varberg, 43281, Sweden
  • Research Site
    Värnamo, 33185, Sweden
  • Research Site
    Västerås, 723 35, Sweden
  • Research Site
    Ystad, 271 82, Sweden
  • Research Site
    Örebro, 701 85, Sweden
  • Research Site
    Östersund, 831 83, Sweden
  • Research Site
    Aberdeen, AB25 2ZN, United Kingdom
  • Research Site
    Ashford, TN24 0LZ, United Kingdom
  • Research Site
    Basingstoke, RG24 9NA, United Kingdom
  • Research Site
    Bath, BA1 3NG, United Kingdom
  • Research Site
    Birmingham, B9 5SS, United Kingdom
  • Research Site
    Blackpool, FY3 8NR, United Kingdom
  • Research Site
    Bradford, BD9 6RJ, United Kingdom
  • Research Site
    Bridgend, CF31 1RQ, United Kingdom
  • Research Site
    Brighton, BN2 5BE, United Kingdom
  • Research Site
    Bristol, BS105NB, United Kingdom
  • Research Site
    Bristol, BS2 8HW, United Kingdom
  • Research Site
    Buckhurst Hill, IG9 5HX, United Kingdom
  • Research Site
    Cambridge, CB2 0AY, United Kingdom
  • Research Site
    Cardiff, CF14 4XW, United Kingdom
  • Research Site
    Clydebank, G81 4DY, United Kingdom
  • Research Site
    Coventry, CV2 2DX, United Kingdom
  • Research Site
    Derby, DE22 3NE, United Kingdom
  • Research Site
    Dundee, DD1 9SY, United Kingdom
  • Research Site
    East Kilbride, G75 8RG, United Kingdom
  • Research Site
    Edgbaston, B15 2WB, United Kingdom
  • Research Site
    Edinburgh, EH16 4SA, United Kingdom
  • Research Site
    Exeter, EX2 5DW, United Kingdom
  • Research Site
    Gillingham, ME7 5NY, United Kingdom
  • Research Site
    Glasgow, G4 0SF, United Kingdom
  • Research Site
    Harefield, UB9 6JH, United Kingdom
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
  • Research Site
    Headington, OX3 9DU, United Kingdom
  • Research Site
    Hull, HU16 5JQ, United Kingdom
  • Research Site
    Kettering, NN16 8UZ, United Kingdom
  • Research Site
    Leeds, LS13EX, United Kingdom
  • Research Site
    Leicester, LE3 9QP, United Kingdom
  • Research Site
    Lincoln, LN2 5QY, United Kingdom
  • Research Site
    Liverpool, L14 3PE, United Kingdom
  • Research Site
    London, NW3 2QG, United Kingdom
  • Research Site
    London, SE5 9RS, United Kingdom
  • Research Site
    London, SW17 0QT, United Kingdom
  • Research Site
    London, W12 0HS, United Kingdom
  • Research Site
    Manchester, M13 9WL, United Kingdom
  • Research Site
    Manchester, M23 9LT, United Kingdom
  • Research Site
    Merthyr Tydfil, CF47 9DT, United Kingdom
  • Research Site
    Middlesborough, TS4 3BW, United Kingdom
  • Research Site
    Newcastle upon Tyne, NE7 7DN, United Kingdom
  • Research Site
    Newport, NP20 2UB, United Kingdom
  • Research Site
    Norwich, NR4 7UY, United Kingdom
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
  • Research Site
    Plymouth, PL6 8DH, United Kingdom
  • Research Site
    Pontyclun, CF72 8XR, United Kingdom
  • Research Site
    Portsmouth, PO6 3LY, United Kingdom
  • Research Site
    Rhyl, LL18 5UJ, United Kingdom
  • Research Site
    Scarborough, YO12 6QL, United Kingdom
  • Research Site
    Sheffield, S5 7AU, United Kingdom
  • Research Site
    Southampton, SO166YD, United Kingdom
  • Research Site
    Stevenage, SG1 4AB, United Kingdom
  • Research Site
    Stoke on Trent, ST4 6QG, United Kingdom
  • Research Site
    Sunderland, SR4 7TP, United Kingdom
  • Research Site
    Swansea, SA6 6NL, United Kingdom
  • Research Site
    Taunton, TA1 5DA, United Kingdom
  • Research Site
    Torquay, TQ2 7AA, United Kingdom
  • Research Site
    Truro, TR1 3LJ, United Kingdom
  • Research Site
    Wakefield, WF1 4DG, United Kingdom
  • Research Site
    Wigan, WN1 2NN, United Kingdom

Showing the first 100 of 103 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jul 2023, 30 months.

Results were first posted in Mar 2025, 1 year 8 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 30 months is below that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2020
First posted
Sep 25, 2020
StartActual
Dec 22, 2020
Primary completionActual
Jul 5, 2023
CompletionActual
Jul 5, 2023
Results first posted
Mar 7, 2025
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04564742
Lead sponsor
AstraZeneca
Collaborators
Uppsala University
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Dec 22, 2020
Primary completion
Jul 5, 2023
Completion
Jul 5, 2023
Results posted
Mar 7, 2025
Last update
Mar 7, 2025

Study contacts

Stefan James
principal investigator · Uppsala University
Jonas Oldgren
study chair · Uppsala University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion